Prevention of Human Rotavirus–Induced Diarrhea in Gnotobiotic Piglets using Bovine Antibody

Joseph P. Schaller, Linda J. Saif, Christopher T. Cordle, Edrick Candler, Jr., Timothy R. Winship, and K. Larry Smith

The efficacy of passively administered bovine antibody for preventing human rotavirus (HRV)–induced diarrhea was investigated using a gnotobiotic pig model. Cows were immunized with inactivated HRV serotypes 1 (Wa) and 2 (S2) and simian rotavirus serotype 3 (SA11), and immune colostrum and milk were collected. Antibody concentrates derived from these materials were fed to germ-free piglets that were subsequently inoculated with HRV Wa. Both viral shedding and diarrhea were effectively reduced or eliminated in a dose-dependent manner as a result of HRV immune antibody feeding. A quantitative virus-neutralizing (VN) antibody method permitted assessment of the functional antibody dose required to achieve a 50% reduction of disease (PD$_{50}$). PD$_{50}$ dose levels of 15.8 and 19.5 × 10$^6$ VN antibody units were determined for inhibition of diarrhea and viral shedding, respectively. Studies reported here provide new information on the quantitative relationship between protective antibody dose and diarrheal disease response.

Human rotavirus (HRV)–induced gastroenteritis is a well-characterized, potentially severe disease that is endemic worldwide. Since its identification as a cause of infant diarrhea in 1973 [1], HRV has been identified as the most common cause of severe childhood diarrhea in developed countries, and HRV ranks second only to enterotoxigenic Escherichia coli as a cause of severe childhood diarrhea in developing countries [2–4]. Rotaviruses also have been identified as a major cause of diarrheal outbreaks in pediatric hospital nurseries [5–7] and day care centers in industrialized nations [8].

Research directed at both active and passive immunophylaxis against HRV-induced diarrhea has been reported. Efforts to develop a satisfactory HRV vaccine have been extensive [9]. Passive antibody approaches have been attempted in piglets [10, 11], cows [12–14], lambs [15], and humans [16–18] with variable success. Prevention of HRV infection and spread in human infants by the feeding of colostrum from cows hyperimmunized with noninactivated monovalent [16] or inactivated tetravalent HRV [18] has been reported. Treatment of infants with acute HRV disease using bovine milk immunoglobulin containing HRV-specific antibody apparently reduces HRV excretion time but not the duration of illness [17]. Although not specifically addressed in these reports [16–18], antibody dose is likely to be of critical importance.

Studies reported here examined the quantitative relationships involved in the prevention of HRV-induced diarrheal disease by passively administered bovine antibody. The gnotobiotic piglet model was used because of the reproducibility of HRV infection and diarrheal disease induction in that system [19].

Materials and Methods

**Piglets.** Gnotobiotic piglets were obtained by hysterectomy and placed in isolators using methods previously described [20].

**Viruses and cells.** HRV serotype 1 Wa (HRV Wa) was initially obtained from R. G. Wyatt (National Institutes of Health, Laboratory of Infectious Diseases, Bethesda, MD) as a virus isolate from a pediatric fecal specimen [21] and was maintained by in vivo passage in gnotobiotic pigs. HRV serotype 2 (S2) was obtained from J. Hughes (Children’s Hospital, Columbus, OH), who originally obtained it from T. Urasawa (Sapporo, Japan) [22]. The SA11 strain (serotype 3), obtained from J. Hughes as passage 8, originally was obtained from H. H. Malherbe [23].

Preparation of challenge virus, infection with HRV Wa, and harvest from cecum and intestinal contents of infected piglets was as described earlier [20, 21, 24, 25]. Briefly, piglets were challenged orally with 2 ml of 10$^2$–10$^7$ fluorescent focus units (FFU)/ml virulent HRV Wa [25]. The animals were euthanized and the intestinal contents were collected near the onset of diarrhea (~48–72 h after challenge). The titer of HRV Wa chosen (2 ml of 4 × 10$^5$ FFU/ml) produced diarrhea in 100% of the challenged piglets in preliminary studies (unpublished data).

For cow immunization and use in virus neutralization assays, pools of plaque-purified Wa, S2, or SA11 were grown in MA-104 cells (continuous rhesus monkey kidney cell line) in 850-mm$^2$ plastic roller bottles using Eagle’s MEM (Whitaker Bionumbers, Walkersville, MD) with 10% fetal calf serum (HyClone Laboratories, Logan, UT). Viruses harvested from infected MA-
104 cell culture fluids were concentrated by ultrafiltration, purified by a proprietary method involving cesium chloride and sucrose density gradient centrifugation, and inactivated using binary ethylencimine [26].

**Cow immunizations.** Groups of cows were immunized with purified trivalent inactivated immunogen preparations according to methods previously described [26, 27]. Briefly, cows were immunized using a combination of intramuscular and intramammary inoculations with 10 ml of trivalent HRV immunogen emulsified in Freund's incomplete adjuvant.

**Antibody preparations.** Colostrum and milk pools were collected and converted to whey by rennin treatment [25] or by acid precipitation. Whey was then either stored frozen in aliquots or purified further to increase the proportion of IgG1 protein. Control materials were prepared in the same manner using colostrum or milk pools from nonimmunized cows. To prevent interference with the diarrheal responses in piglets due to the nonsterile nature of the test products and resulting microbial contamination, antibody concentrates and matched control materials were irradiated (0.4 Mrad) or treated with antibiotics (gentamicin, 100 μg/ml; vancomycin, 300 μg/ml; and fungizone, 20 μg/ml).

**Characterization of test product potency.** Quantitation of virus-neutralizing (VN) antibody in the test product was accomplished using an infected cell reduction assay in microtiter plates, modified from that of Gerna et al. [28]. Briefly, serial twofold dilutions of antibody were mixed with equal volumes of trypsin-activated HRV Wa appropriately diluted to yield 500–1000 MA-104 cell infectious units per well in 96-well microtiter plates. After incubation (1 h at room temperature), the virus-antibody reaction mixtures were added to MA-104 cell monolayers in microtiter plates and incubated for 12–14 h at 37°C in 5% CO2. After incubation, the monolayers were fixed with ethanol and stained for detection of infected cells using an immunoperoxidase method consisting of the sequential addition of bovine anti-HRV antibody, horseradish peroxidase-conjugated rabbit anti-bovine IgG, and diaminobenzidine substrate. Residual infectivity was determined at each dilution of test antibody, and the VN antibody titer was calculated at a virus survival of 37% [29]. Antibody potency (VN antibody units [VNU] per milligram of IgG1) was determined as the VN antibody titer per unit volume of antibody (0.05 ml) in the reaction mixture (0.10 ml) divided by the IgG1 concentration. Bovine IgG1 concentrations were determined using radial immunodiffusion (ICN Biomedicals, Costa Mesa, CA) and used for the determination of bovine immunoglobulin specific activity. Standardized preparations of infectious virus and reference HRV-immune bovine antibody were used to maintain consistent antigen and antibody equivalents [29] and hence optimize assay accuracy. VN antibody determinations on piglet sera were made using a plaque-reduction assay [25].

**Piglet feeding regimen and challenge studies.** Protection studies were conducted in litter sizes of eight piglets. Within each litter, four or five piglets were fed HRV-specific antibody, two or three were fed control bovine immunoglobulin, and at least two were used as challenge controls and did not receive any bovine immunoglobulin. Piglets were fed ~70 ml of Similac with iron (SWI; Ross Laboratories, Columbus, OH) three times per day on the first and second days after birth.

Feeding of test preparations began on day 3, followed by three test preparation feedings daily for various intervals (5, 8, or 16 days). Test preparation feedings (12–30 ml, three times/day) were supplemented with SWI for a total volume of 250–360 ml/day. Piglets were challenged orally at age 4 days with 2 ml of an intestinal contents suspension of virulent HRV Wa (4 X 10⁶ FFU/ml). Rectal swabs were taken and the piglets were observed for signs of disease daily [25]. Stool characteristics were scored as normal (brown solid feces), mild diarrhea (light-colored, semisolid feces), or profuse diarrhea (copious yellow, watery stools). Blood samples were obtained from all piglets before HRV challenge and at ~2 and 3–5 weeks of age. Rectal fluids were examined for infectious virus (viral shedding) using an infected-cell assay in microtiter plates (infected cells detected using immunofluorescence) [30].

**Results**

**Immunoglobulin preparations and feeding regimen.** Eleven colostrum or milk HRV-immune antibody preparations and four preparations from nonimmunized cows (table 1) were examined for their ability to prevent HRV-induced diarrhea in piglets. Immune preparations 2 and 8 were irradiated colostrum–derived products, whereas all others consisted of antibiotic-treated milk immunoglobulin concentrates (table 1). Fed antibody dose levels ranged from a high of 89.3 X 10⁶ VNU/day contained in 1.72 g of IgG1 to 3.6 X 10⁶ VNU in 70 mg of IgG1. Nonimmune control preparations were fed to within-litter controls at IgG1 dosing levels similar to the HRV-immune dose levels tested.

Bovine immunoglobulin preparations were analyzed for IgG1 and VN antibody activity and the concentrations adjusted to the desired dose before feeding. Characterization of the HRV-specific and control nonimmune materials and feeding regimen (dose and duration of feeding) are shown in table 1. The HRV Wa–specific VN antibody potency levels of the γ-irradiated colostral whey antibody (immune) preparations 2 and 8 were the lowest of all preparations tested (9.4 and 5.5 X 10⁶ VNU/mg of IgG1, respectively). All other preparations were milk-derived immunoglobulin concentrates with VN antibody potency levels (HRV-specific) ranging from 35 to 70 X 10⁶ VNU/mg of IgG1 (mean ± SD, 50.5 ± 13.8 X 10⁶). Nonimmune control immunoglobulin preparations had a mean potency of 5.1 X 10⁶ VNU/g of IgG1, 7- to 14-fold lower than the immunoglobulin concentrates from HRV-immunized cows.
Table 1. Human rotavirus (HRV)-specific bovine immunoglobulin preparations and feeding regimen in gnotobiotic piglets.

| Preparations (feeding groups)* | No. of days fed | HRV Wa VN antibody specific activity | Dose fed/day | |
|-------------------------------|----------------|------------------------------------|--------------|-----|
| Immune                        |               |                                    |              |     |
| 1                             | 16            | 43.3                               | 1.72         | 89.3 |
| 2                             | 5             | 9.4                                | 6.17         | 58.0 |
| 3                             | 16            | 35.0                               | 1.57         | 55.0 |
| 4                             | 8             | 42.8                               | 1.13         | 48.0 |
| 5                             | 5             | 36.9                               | 1.21         | 44.6 |
| 6                             | 16            | 61.1                               | 0.50         | 30.5 |
| 7                             | 8             | 42.8                               | 0.56         | 24.0 |
| 8                             | 5             | 5.5                                | 3.35         | 18.3 |
| 9                             | 16            | 71.5                               | 0.23         | 16.5 |
| 10                            | 16            | 70.0                               | 0.11         | 7.7  |
| 11                            | 16            | 51.3                               | 0.07         | 3.6  |
| Nonimmune                     |               |                                    |              |     |
| 1                             | 5             | 2.8                                | 2.90         | 8.2  |
| 2                             | 5             | 3.6                                | 1.00         | 3.6  |
| 3                             | 16            | 6.7                                | 0.50         | 3.3  |
| 4                             | 16            | 7.0                                | 0.12         | 0.8  |

NOTE. VN, virus-neutralizing.

* Immune preparations 2 and 8 were derived from the pooled colostral whey. All other immune preparations were milk-derived. Nonimmune preparation 1 was derived from pooled colostral whey. Other nonimmune preparations were milk-derived.

Specific activity = VN antibody units per milligram of IgG1.

Disease response in control piglets. The HRV-induced diarrheal disease response using the gnotobiotic piglet model was characterized by determining the occurrence of viral shedding and diarrhea in control piglets (figure 1). The profile of the occurrence of HRV shedding and diarrhea was determined for the 2-week interval following inoculation with HRV Wa. Infectious virus was shed by 100% of the 11 control piglets on postchallenge days 2 and 3 and continued to be shed in most of the piglets through days 6 and 7. Likewise, the occurrence of diarrhea (mild, profuse) approached 100% during this interval.

To compare the disease responses among various feeding groups, the interval from day 1 through day 6 after virus challenge was analyzed in subsequent experiments for the occurrence of infectious viral shedding and the occurrence of diarrhea. This interval corresponded with the prevalence of diarrheal disease and therefore provided the best opportunity to compare disease responses between groups. Diarrheal disease was scored as mild or profuse on the basis of fecal color, consistency, and volume of the feces compared with normal. Profuse diarrhea occurred with highest frequency during postchallenge days 3–7 (figure 1).

Disease response in HRV Wa-challenged, passive antibody-fed piglets. Diarrheal disease responses for three groups of piglets fed HRV-immune antibody, one fed nonimmune bovine immunoglobulin, and one fed unsupplemented SWI are shown in table 2. Antibody from nonimmunized cows (nonimmune 1) slightly delayed the appearance of diarrheal disease and HRV shedding compared with SWI-fed controls. An immune antibody dose containing fivefold higher VNU than the control material (immune 5, 44.6 × 10⁶ VNU/day for 5 days) appeared to further delay the onset of disease (table 2). The feeding of a slightly higher dose (immune 2) eliminated viral shedding and diarrhea until well after the antibody feeding had stopped on postinfection day 3 (mild diarrhea at day 11). Infectious HRV shedding and diarrhea were completely eliminated by feeding the high-VN antibody dose (immune 1, 89.3 × 10⁶ VNU/day) for all 16 days of observation.

Results obtained for all piglets examined in these studies are summarized in table 3. Protection from HRV Wa challenge for piglets observed 1–6 days after challenge is shown for piglets fed at different dose levels calculated as a percent-

![Figure 1](image-url)
Table 2. Viral shedding and diarrheal responses in human rotavirus (HRV) Wa–challenged gnotobiotic piglets fed immune or nonimmune bovine IgG1 or control material.

| Feeding regimen | Dose/day (VN antibody units × 10^6) | Animal no. | Viral shedding and diarrheal response by days after exposure to HRV Wa challenge |
|----------------|-------------------------------------|------------|--------------------------------------------------------------------------------|
|                |                                     |            | -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
|                |                                     |            | M M M M P+ P+ P+ P+ P+ P+ M M |
| Immune         |                                     |            | 1-5 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| 1              | 16                                  | 89.3       | +   | M M M |
| 2              | 5                                   | 58.0       | +   | M M M |
| 3              | 4                                   |           | +   | M   |
| 4              | 5                                   | 44.6       | +   | P+ P+ P P P P P P P P P P M M |
| 5              | 6                                   |           | +   | P+ P+ P+ P P P P P P P P P P P P M |
| Nonimmune      |                                     |            | +   | M+ P+ M+ P+ P+ P P M M M M |
| 1              | 5                                   | 8.2        | +   | M+ P+ M+ P+ P+ P P M M M M |
| 2              | 3                                   |           | +   | M+ P+ M+ P+ P+ P P M M M M |
| 3              | 4                                   |           | +   | M+ P+ M+ P+ P+ P P M M M M |
| 4              | SWI control                         | 0          | +   | P+ P+ P+ P+ P+ P P M M M M |

NOTE: SWI, Similac with iron; VN, virus-neutralizing; M, mild diarrheal response; P, profuse diarrheal response; +, positive HRV in feces.
* Piglets were fed immune or nonimmune test material beginning on the day before challenge and continuing for a total of either 5 or 16 days as shown.

age of the control group disease response (diarrhea and viral shedding). Low-level protection was observed in piglets fed IgG1 from nonimmunized cows (table 3) and was roughly equivalent to that observed with the feeding of similar VN antibody doses from immunized cows.

Protection from disease and viral shedding appeared to be clearly influenced by the total VN antibody dose of the bovine immunoglobulin fed. In addition, moderate levels of bovine antibody (16.3 and 30.5 × 10^6 VNU/day) fed for a longer period (16 days) reduced the diarrheal disease response (50% and 16.7% of diarrhea days, respectively; table 3). These doses likely provided effective prevention of infectious virus breakthrough. Short-term feeding for 5 days (1 day before to 3 days after challenge) with a slightly higher VN antibody dose (44.6 × 10^6 VNU/day) prevented diarrheal disease during antibody feeding and delayed the disease response to HRV challenge (tables 2 and 3).

Figure 2 summarizes the dose-response data observed in all piglets studied and presents viral shedding and diarrheal disease responses in immune-fed (10 groups), non-immune-fed (2 groups), and control piglets. For this analysis, the response to HRV challenge is presented for the period 2–6 days after challenge. Results are similar to those for days 1–6, but with a higher incidence of disease due to elimination of the first day after challenge. Determination of the antibody dose–disease response relationship provided the opportunity to calculate protective dose levels required to lower the incidence of HRV-induced diarrhea or viral shedding by 50%. Antibody dose levels yielding PD50 were determined by regression analysis using disease response and viral shedding data for days 1–6 (figure 3). Linear models were used for determining the relationships between disease and antibody dose. The null hypothesis (no VN antibody dose effect) was rejected at a significance level of P = .0001 for both viral shedding (R^2 = 86%) and diarrhea (R^2 = 85%). The PD50 for HRV shedding was similar (19.5 × 10^6 VN antibody units) to that for diarrhea (15.8 × 10^6 VN antibody units).

Seroconversion studies. The ability of antibody-fed and control piglets to respond immunologically to virulent HRV Wa challenge was tested by determining the serum VN antibody titers before (1–4 days of age) and after challenge (table 4). All piglets, including high-dose antibody-fed piglets, seroconverted after challenge. Some reduction in VN antibody response to challenge was apparent in the piglets receiving high antibody dose levels.

Discussion
Rotaviruses are highly stable [32–34], are infectious at very low concentrations [35], and can be continuously shed by chronically infected, asymptomatic individuals [36]. Con-
Table 3. Disease responses in human rotavirus (HRV)–challenged gnotobiotic piglets fed IgG from HRV-immunized or unimmunized cows or control material.

| Feeding regimen | Dose/day (VN units $\times 10^6$) | Piglets per group | No. of days fed | Response to challenge, no. of days (%) | % protection$^t$ |
|-----------------|----------------------------------|------------------|-----------------|--------------------------------------|-----------------|
| Immune          |                                  |                  |                 | Viral/shedding                        |                 |
| 1               | 89.3                             | 5                | 16              | 0/30                                 | 100             |
| 2               | 58.0                             | 4                | 5               | 0/24                                 | 100             |
| 3               | 55.0                             | 4                | 16              | 1/24 (4)                             | 97.4            |
| 4               | 48.0                             | 2                | 8               | 3/12 (25)                            | 83.9            |
| 5               | 44.6                             | 4                | 5               | 6/24 (25)                            | 75.8            |
| 6               | 30.5                             | 2                | 16              | 5/12 (41.7)                          | 62.3            |
| 7               | 24.0                             | 2                | 8               | 4/12 (33.3)                          | 78.5            |
| 8               | 18.3                             | 4                | 5               | 7/24 (29.2)                          | 46.2            |
| 9               | 16.3                             | 2                | 16              | 8/12 (66.7)                          | 24.7            |
| 10              | 7.7                              | 2                | 16              | 8/12 (66.7)                          | 8.5             |
| 11              | 3.6                              | 2                | 16              | 9/12 (75)                            | 3.2             |
| Nonimmune       |                                  |                  |                 |                                      |                 |
| 1               | 8.2                              | 6                | 5               | 17/36 (47.2)                         | 33.6            |
| 2               | 3.6                              | 2                | 5               | 8/12 (66.7)                          | 13.9            |
| 3               | 3.3                              | 2                | 16              | 8/12 (66.7)                          | 13.9            |
| 4               | 0.8                              | 2                | 16              | 10/12 (83.3)                         | 0               |
| SW1 control     | 0                                | 11               | 0               | 85/102 (83.3)                        | 0               |

NOTE. VN, virus-neutralizing; SW1, Similac with iron.

$^*$ Response between days 1–6 after challenge with virulent HRV Wa. Data are group values: days of viral shedding or diarrhea/total days observed expressed as percentage.

$^t$ % protection = $[\%$ days (viral shedding + diarrhea) of antibody-fed group]/$[\%$ days (viral shedding + diarrhea) of control group}] $\times$ 100 – 100.

sequently, eradication of group A rotaviruses is not likely, and exposure to these viruses is inevitable [37]. Effective active or passive (or both) immune prevention methods are therefore essential to reduce the morbidity of rotaviral diarrhea. Development of live, attenuated HRV vaccine continues to offer significant hope for providing this protection, but extensive efforts to date have not resulted in an acceptable vaccine [38].

Passive immune protection methods may prove to be useful for at-risk populations, providing the needed margin of safety against rotaviral diarrhea. Reports of successful passive antibody immunoprophylaxis in hospitalized patients [16, 18] suggests that this supportive procedure may significantly reduce the incidence of nosocomial HRV infection. As described by Davidson et al. [18], the value of such an antibody preparation is broad, with potential for use in hospi-

Figure 2. Disease (virus shed in feces and diarrhea: mild and profuse) for groups of gnotobiotic piglets fed human rotavirus (HRV)–immune and nonimmune (*) bovine immunoglobulin. Daily antibody dose (virus-neutralizing [VN] units fed/day $\times 10^6$) and IgG1 (g fed/day) for each group tested. Mild diarrhea, profuse diarrhea, and virus shed in feces are shown as percentage of days (2–6) observed.
Figure 3. Determination of 50% of protective dose (PD$_{50}$) for human rotavirus (HRV)-immune bovine immunoglobulin concentrates in HRV strain Wa-challenged gnotobiotic piglets (16 feeding groups, total $n = 62$). The prevalence of viral shedding (A) or diarrhea (B), observed from days 1–6 (percentage of days), are plotted for each daily antibody dose level tested. PD$_{50}$ levels of 15.8 (range, 10.5–21.1) and 19.5 (range, 14.6–24.4) $\times 10^6$ virus-neutralizing (VN) units fed/day were determined for diarrhea and viral shedding, respectively. End points for each range were determined from the 95% confidence limits of the response regressions at VN antibody dose = PD$_{50}$. Each linear model was fit omitting the response at VN antibody dose = 89.3 $\times 10^6$ VN units. Significance levels were $P = .0001$ for both models. Data from the nonimmune-antibody-fed groups, immune antibody-fed groups, and control (Similac with iron–fed) group were all used in the regression analyses.

The gnotobiotic piglet represents a useful model for understanding these dose-response relationships. Gnotobiotic piglets are susceptible to challenge by HRV serotypes 1 (Wa) [21] and 3 (M strain) (unpublished data), yielding diarrhea by a similar mechanism and with similar kinetics to that shown in the human disease. This model represents a considerable advantage, as it is possible to test prototype HRV-specific antibody materials by challenging with HRV strains. Piglet gut physiology (e.g., lack of permeability to intact antibody) and diarrheal response are also similar to that of the human infant [39].

Results of studies reported here show the dose-dependent, passive antibody protection from infectious HRV challenge (viral shedding and diarrhea) in piglets fed bovine IgG concentrates from immunized cows. A clear relationship between fed antibody dose (as measured using an in vitro VN method) and diarrheal disease response was established. Because of the variability in antibody titer observed in colostrum and milk immunoglobulin preparations, the conversion to specific activity (VNU per milligram of IgG1) provided a convenient means of standardizing antibody potency. The value of this conversion appears to be confirmed by the relationship observed between antibody dose and disease response. This correlation between in vivo protection and in vitro-determined VN antibody potency will be helpful in planning and implementing clinical investigations with these antibodies.

Because of multiple passage in gnotobiotic piglets, the HRV Wa strain used in these studies may show increased virulence for the porcine intestinal tract. This would then
Table 4. Virus-neutralizing (VN) antibody seroconversion of human rotavirus (HRV)-challenged gnotobiotic piglets fed IgG from HRV immunized and unimmunized cows.

| Group          | Dose/day (VN units x 10^6) | Response (% days)* | VN antibody response by days after challenge |
|----------------|---------------------------|--------------------|---------------------------------------------|
|                |                           | Viral shedding     | 3 to 0 | 14   | 21 to 30 |
| Immune         |                           | Diarrhea           |        |      |          |
| 1              | 89.3                      | 0                  | <5 (5) | 11 (5)| 26 (5)  |
| 2              | 58.0                      | 0                  | <5 (4) | ND   | 104 (4) |
| 3              | 55.0                      | 4                  | <5 (4) | ND   | 52 (4)  |
| 4              | 48.4                      | 25                 | <5 (2) | 21 (2)| 75 (2)  |
| 5              | 44.6                      | 25                 | <5 (4) | 150 (2)| 87 (2) |
| 6              | 30.5                      | 41.7               | <5 (1) | ND   | 147 (2) |
| 7              | 24.0                      | 33.3               | <5 (2) | 85 (2)| 356 (2) |
| 8              | 18.3                      | 29.2               | <5 (4) | 65 (4)| 33 (1)  |
| 9              | 16.5                      | 66.7               | <5 (2) | ND   | 87 (2)  |
| 10             | 7.7                       | 66.7               | <5 (2) | 310 (1)| 258 (2)|
| 11             | 3.6                       | 75                 | <5 (2) | 30 (1)| 120 (1) |
| Nonimmune      |                           |                    |        |      |          |
| 1              | 8.2                       | 47.2               | <5 (6) | ND   | ND      |
| 2              | 3.6                       | 66.7               | <5 (2) | ND   | 280 (1) |
| 3              | 3.3                       | 66.7               | <5 (2) | ND   | 629 (2) |
| 4              | 0.8                       | 83.3               | <5 (2) | 270 (1)| ND      |
| SWI control    | 0                         | 83.3               | ND     | ND   | 337 (10) |

NOTE. SWI, Similac with iron; ND, not determined.

* Response between days 1-6 after challenge with virulent HRV Wa. Data are group values for the fraction (days of viral shedding or diarrhea/total days examined) expressed as percentage.

† Plaque reduction neutralization expressed as geometric mean titer (number of piglets tested at each interval).

represent a particularly severe test of passive antibody efficacy in the piglet model. As shown here, clear protection endpoints can be seen in pigs that received sufficient amounts of immune bovine IgG.

Our results suggested that some reduction in seroconversion might have occurred at the highest antibody levels administered. This is not unexpected given the substantial decrease in viral antigen shedding associated with the bovine antibody dose fed. Moderately high levels of HRV VN antibody were seen in sera of piglets that were protected from disease with high-dose bovine antibody, reflecting the presence of sufficient immunogenic HRV antigen likely representing progeny virus from infected intestinal epithelium. Similar seroconversion levels were shown to be correlated with protection in related studies using porcine rotavirus challenge [10] and in human infants [16] fed rotavirus-immune bovine colostrum. It is doubtful that passively administered bovine antibody is responsible for VN antibody in piglet serum, as gut closure in the piglet occurs within the first 24 h after birth.

The extent of diarrheal disease and viral shedding was influenced by both VN antibody dose and the duration of feeding. The data presented here suggest that maximum protection is achieved as long as the immune antibody is present in the gastrointestinal tract during the period of risk and during the interval corresponding to the normal course of the disease.

Acknowledgments

We thank T. Umphrey and G. Duska-McEwen for excellent technical support and W. Malone and J. Dugle for statistical evaluations.

References

1. Bishop RF, Davidson GP, Holmes IH, Buck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;2:1281-3.
2. Kapikian AZ, Kim HW, Wyatt RG, et al. Human reovirus-like agent as the major pathogen associated with “winter” gastroenteritis in hospitalized infants and young children. N Engl J Med 1976;294:965-72.
3. Black RE, Merson MH, Huf I, et al. Incidence and severity of rotavirus and Escherichia coli diarrhea in rural Bangladesh: implications for vaccine development. Lancet 1981;1:141-3.
4. Davidson GP, Bishop RF, Townley RRW, Holmes IH, Buck BJ. Importance of a new virus in acute sporadic gastroenteritis in children. Lancet 1975;1:242-6.
5. Flewett TH, Bryden AS, Davies H, Morris CA. Epidemic viral enteritis in a long-stay children's ward. Lancet 1975;1:424-6.
6. Murphy AM, Albrey MB, Crew EB. Rotavirus infections of neonates. Lancet 1977;2:1149-50.
7. Rodriguez WJ, Kim WK, Brandt CD, Fletcher AB, Parrott RH. Rotavirus: a cause of nosocomial infection in the nursery. J Pediatr 1982;101:274-7.
8. Pickering LK, Bartlet AV III, Reves RR, Morrow A. Asymptomatic rotavirus before and after rotavirus diarrhea in children in day care centers. J Pediatr 1988;112:361-5.
9. Haffejee IE. The status of rotavirus vaccines in 1990. J Infect 1991;22:119-28.
10. Bridger JC, Brown JF. Development of immunity to porcine rotavirus in piglets protected from disease by bovine colostrum. Infect Immun 1981;31:906-10.
11. Leece JG, Leary HL, Clare DA, Batema RP. Protection of agammaglobulinemic piglets from porcine rotavirus infection by antibody to Simian rotavirus SA II. J Clin Microbiol 1991;29:1382-6.
12. Snodgrass DR, Fahey KJ, Wells PW, Campbell L, Whitelaw A. Passive immunity in calf rotavirus infection: maternal vaccination increases and prolongs immunoglobulin G antibody secretion in milk. Infect Immun 1980;28:34-49.
13. Saif LJ, Redman DR, Smith KL, Theil KW. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized or nonimmunized cows. Infect Immun 1983;41:1118-31.
14. Castrucci G, Frigeri F, Ferrari M, Aldrovandi V, Tassini F, Gatti R. The protection of newborn calves against experimental rotavirus infection by feeding mammary secretions from vaccinated cows. Microbiologica 1988;11:379-85.
15. Snodgrass DR, Wells PW. Rotavirus infection in lambs: studies on passive protection. Arch Virol 1976;52:201-5.
16. Ebina T, Sato A, Kitaoka K, et al. Prevention of rotavirus infection by oral administration of cow colostrum containing anti-human rotavirus antibody. Med Microbiol Immunol 1985;174:177-85.
17. Hillert H, Brussow H, Mietens C, Sidoti J, Lerner L, Werchau H. Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis 1987;156:156-66.
18. Davidson GP, Daniels E, Nunan H, et al. Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 1989;1:709-12.
19. Thiel KW, Bohl EH, Cross RF, Kohler EM, Agnes AG. Pathogenesis of porcine rotaviral infection in experimentally inoculated gnotobiota pigs. Am J Vet Res 1978;39:213-20.
20. Bohl EH, Saif LJ, Theil KW, Agnes AG, Cross RF. Porcine parvovirus: detection, differentiation from rotavirus and pathogenesis in gnotobiota pigs. J Clin Microbiol 1982;25:812-8.
21. Wyatt RG, James WD, Bohl EH, et al. Human rotavirus type 2: cultivation in vitro. Science 1980;207:189-91.
22. Urasawa S, Urasawa T, Taniguchi K. Three human rotavirus serotypes demonstrated by plaque neutralization of isolated strains. Infect Immun 1982;38:781-4.
23. Mahlerbe HH, Strickland-Chomley M, Simian virus SA11 and the related O agent. Arch Gesamte Virusforsch 1967;22:235-8.
24. Saif LJ. Passive immunity to coronavirus and rotavirus infections in swine and cattle: enhancement by maternal vaccination. In: Tzipori S, ed. Infectious diarrhea in the young. Amsterdam: Elsevier Science, 1985;456-67.
25. Bohl EH, Theil KW, Saif LJ. Isolation and serotypes of porcine rotaviruses and antigenic comparison with other rotaviruses. J Clin Microbiol 1984;19:105-11.
26. Saif LJ, Smith KL. Rotavirus immunization of cows and passive protection in calves: a review. In: Acres SD, ed. Proceedings of the 4th International Symposium on Neonatal Diarrhea. Saskatoon, Canada: Veterinary Infectious Disease Organization, 1983;394-423.
27. Saif LJ, Smith KL, Landmeier BL, Bohl EH, Theil KW, Todhunter DA. Immune response of pregnant cows to bovine rotavirus immunization. Am J Vet Res 1984;45:49-58.
28. Gerna G, Battaglia M, Milienes G. Serotyping of cell culture adapted subgroup 2 human rotavirus strains by neutralization. Infect Immun 1984;43:722-9.
29. Dulbecco R, Vogt M, Strickland AGR. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology 1956;2:162-205.
30. Terrett LA, Saif LJ, Theil KW, Kohler EM. Physiochemical characterization of porcine pararotavirus and detection of virus and viral antibodies using cell culture immunofluorescence. J Clin Microbiol 1987;25:268-72.
31. Finney JD. Probit analysis. In: Finney JD, ed. Estimation of the median effective dose. New York: Cambridge University Press, 1971: 20-49.
32. Moe K, Shirley JA. The effects of relative humidity and temperature on the survival of human rotavirus in feces. Arch Virol 1982;72:179-86.
33. Ansari SA, Sattar SA, Springthorpe VS, Wells GA, Tostowaryk W. Rotavirus survival on human hands and transfer of infectious virus to animate and nonporous inanimate surfaces. J Clin Microbiol 1988;26:1513-8.
34. Snodgrass DR, Herring JA. The action of disinfectants on lamb rotavirus. Vet Rec 1977;101:19-81.
35. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR, Schiff GM. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis 1986;154:871-80.
36. Holdaway MD, Kalmakoff J, Todd BA, Jennings LC. Rotavirus infection in a small community. J Med Virol 1985;15:389-98.
37. Theil KW. Group A rotaviruses. In: Saif LJ, Theil KW, eds. Viral diarrhea of man and animals. Boca Raton, FL: CRC Press, 1990;35-72.
38. Puzzling diversity of rotaviruses. Lancet 1990;335:573-5.
39. Tumbleson ME. Swine in biomedical research. New York: Plenum Press, 1986.